These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 21179900)
1. [Clinical rationale for using dabigatran etexilate in the complex treatment of venous thromboembolism]. Sukovatykh BS; Savchuk OF Khirurgiia (Mosk); 2010; (10):78-82. PubMed ID: 21179900 [No Abstract] [Full Text] [Related]
2. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. Schulman S; Kearon C; Kakkar AK; Mismetti P; Schellong S; Eriksson H; Baanstra D; Schnee J; Goldhaber SZ; N Engl J Med; 2009 Dec; 361(24):2342-52. PubMed ID: 19966341 [TBL] [Abstract][Full Text] [Related]
3. Dabigatran etexilate for prevention of venous thromboembolism. Eikelboom JE; Weitz JI Thromb Haemost; 2009 Jan; 101(1):2-4. PubMed ID: 19132179 [No Abstract] [Full Text] [Related]
4. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Eriksson BI; Dahl OE; Rosencher N; Kurth AA; van Dijk CN; Frostick SP; Prins MH; Hettiarachchi R; Hantel S; Schnee J; Büller HR; Lancet; 2007 Sep; 370(9591):949-56. PubMed ID: 17869635 [TBL] [Abstract][Full Text] [Related]
5. Insights from the dabigatran versus warfarin trial in patients with venous thromboembolism (the RE-COVER trial). Prandoni P; Taher A Expert Opin Pharmacother; 2010 Apr; 11(6):1035-7. PubMed ID: 20307227 [TBL] [Abstract][Full Text] [Related]
6. Efficacy and safety of dabigatran etexilate for the prevention of venous thromboembolism following total hip or knee arthroplasty. A meta-analysis. Wolowacz SE; Roskell NS; Plumb JM; Caprini JA; Eriksson BI Thromb Haemost; 2009 Jan; 101(1):77-85. PubMed ID: 19132192 [TBL] [Abstract][Full Text] [Related]
7. [Dabigatran versus warfarin in the treatment of acute venous thromboembolism. Results of the RE-COVER study]. Liakishev AA Kardiologiia; 2010; 50(3):80-1. PubMed ID: 20459411 [No Abstract] [Full Text] [Related]
8. [Dabigatran: a new therapeutic option for therapy and prophylaxis of thromboembolic diseases?]. Gassanov N; Caglayan E; Erdmann E; Er F Dtsch Med Wochenschr; 2010 Feb; 135(6):256-9. PubMed ID: 20104442 [No Abstract] [Full Text] [Related]
9. Dabigatran etexilate: an oral direct thrombin inhibitor for prophylaxis and treatment of thromboembolic diseases. Baetz BE; Spinler SA Pharmacotherapy; 2008 Nov; 28(11):1354-73. PubMed ID: 18956996 [TBL] [Abstract][Full Text] [Related]
10. Hemopericardium in a patient treated with dabigatran etexilate. Barton CA; McMillian WD; Raza SS; Keller RE Pharmacotherapy; 2012 May; 32(5):e103-7. PubMed ID: 22488474 [TBL] [Abstract][Full Text] [Related]
11. Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery. ; Ginsberg JS; Davidson BL; Comp PC; Francis CW; Friedman RJ; Huo MH; Lieberman JR; Muntz JE; Raskob GE; Clements ML; Hantel S; Schnee JM; Caprini JA J Arthroplasty; 2009 Jan; 24(1):1-9. PubMed ID: 18534438 [TBL] [Abstract][Full Text] [Related]
12. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. van Ryn J; Stangier J; Haertter S; Liesenfeld KH; Wienen W; Feuring M; Clemens A Thromb Haemost; 2010 Jun; 103(6):1116-27. PubMed ID: 20352166 [TBL] [Abstract][Full Text] [Related]
13. Rash associated with dabigatran etexilate. To K; Reynolds C; Spinler SA Pharmacotherapy; 2013 Mar; 33(3):e23-7. PubMed ID: 23400964 [TBL] [Abstract][Full Text] [Related]
14. Dabigatran etexilate: management in acute ischemic stroke. Javedani PP; Horowitz BZ; Clark WM; Lutsep HL Am J Crit Care; 2013 Mar; 22(2):169-76. PubMed ID: 23455868 [TBL] [Abstract][Full Text] [Related]